The MiningNewsWire Podcast

Ceylon Graphite Corp. (TSX.V: CYL) (OTC: CYLYF) (FSE: CCY) announced that Don Baxter has joined the Board of Directors of the company. Don Baxter is one of the premier graphite experts outside of China, having built one of only two producing graphite mines in North America. He is presently Chief Executive Officer and Director of Applied Graphite Technologies Corp. Prior to this, Don served as President, CEO and Executive Director of Alabama Graphite Corp, successfully completing the company’s disruptive Preliminary Economic Assessment (PEA) and introducing a new, battery-focused strategy.

InvestorBrandNetwork (“IBN”), an innovative corporate communications agency, content distributor and wire-grade press service via NetworkNewsWire, has completed its coverage of the 12th annual LD Micro Main Event, one of the largest and most influential independent conferences in the small-cap space. A five-year sponsor of LD Micro, IBN attended this year’s Main Event to engage with executives from the 275+ public companies that presented at the conference. IBN also provided widespread exposure through published corporate overviews and delivered real-time social media coverage for participating companies.

While big streaming companies battle it out for supremacy, the real winners of an epic battled dubbed the “streaming wars” may have already emerged: the production companies that stand to profit in a big way from the exploding demand for SVoD content. As digital streaming steadily eclipses all other forms of in-home entertainment delivery, an entertainment war has erupted among leading subscription video on demand (SVoD) providers. These streaming wars have opened the gate for newer production companies to step up and cash in by funneling fresh content to hungry SVoDs. The battle has already resulted in some big winners, including film-production companies, such as Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), that are lining up to satisfy the voracious content appetite of these SVoD giants. As on-demand media streaming continues to rival — and in some cases supplant — every other form of entertainment delivery, major streaming service providers such as Apple Inc. (NASDAQ: AAPL), Netflix Inc. (NASDAQ: NFLX), The Walt Disney Company (NYSE: DIS) and Amazon.com Inc. (NASDAQ: AMZN) are also duking it out for dominance.

3D-printing technology has arrived and appears ready to beneficially disrupt every field it touches. Additive manufacturing, better known as three-dimensional or 3D printing, has potential to change the world. However, the full promise of the technology has been stymied due to the high costs and complexities of end-product inspection and quality control. With its pioneering PrintRite3D(R) software, Sigma Labs Inc. (NASDAQ: SGLB) appears to be ready to help unleash the transformative forces of 3D printing and usher in what’s been called the fourth industrial revolution. Aerospace has embraced 3D printing and, for the first time in the industry, Sigma Labs’ software makes possible nondestructive quality assurance during the 3D printing of metal parts, uniquely allowing errors to be corrected in real time. The sector has been searching for just such a validated tool and method to raise quality and cut costs, scale production, and bring 3D printing even more into mainstream manufacturing. Using 3D printing, Pratt & Whitney, a division of United Technologies Corporation (NYSE: UTX), delivered the first entry-into-service jet-engine parts ever produced. Honeywell International Inc. (NYSE: HON) has qualified more 3D-printed aircraft parts with the FAA than any of its rivals, noting that “3D printing technology is real and it’s fantastic.” Achieving design solutions that have been inconceivable in the past, Boeing (NYSE: BA) has applied the technology to airplanes, missiles, satellites and spacecraft. These amazing achievements are made possible by 3D-printing technology, guided and directed by advanced-engineering simulation software from companies such as ANSYS (NASDAQ: ANSS) and now, it appears, significantly accelerated, enhanced and simplified by the quality assurance software of Sigma Labs.

Heralded as the fourth industrial revolution, 3D printing is about to transform the $12 trillion global manufacturing sector. Sigma Labs Inc. (NASDAQ: SGLB) is on the verge of unleashing the dynamic forces of additive metal manufacturing that have been restrained. Long heralded as the fourth industrial revolution, 3D metal printing and its full potential have been stalled due to the high cost and complexities of end-product inspection and quality control. Sigma Labs’ PrintRite3D(R) software represents a seismic shift in the quality-assurance process in the manufacture of 3D-printed metal components, and the entire sector is poised for extraordinary growth. Software giant Autodesk Inc. (NASDAQ: ADSK) has aggressively moved into the space developing software across a range of uses in 3D printing. With nearly three decades of experience, Materialise NV (NASDAQ: MTLS) has integrated Sigma Labs’ PrintRite3D technology with its Materialise MCP controller, and the companies will jointly demonstrate the latest version of the software platform to the global elite of additive manufacturing at the Formnext exhibition. Siemens AG (OTC: SIEGY) is a global leader in industrializing 3D printing and assisted Sigma in evolving the early version of PrintRite3D INSPECT version 2.0 towards 5.0. Even more momentous, General Electric’s (NYSE: GE) Baker Hughes division has begun the final phase of the PrintRite3D rapid-test and evaluation program, the last step before commercial orders.

IBN's communication director, Jonathan Keim, presented "IR and the Importance of Content Strategies" on November 13, 2019, at the Westin in Times Square during the National Investment Banking Association (NIBA) conference. Thousands of investment professionals are involved with NIBA, representing more than 60 key industry services, along with 8,800+ registered representatives that have in excess of $78 billion in assets under management. To date, the association’s members have raised over $17 billion and are responsible for 90% of all Initial Public Offerings under $20 million.

IBN's communication director, Jonathan Keim, presented "IR and the Importance of Content Strategies" on November 13, 2019, at the Westin in Times Square during the National Investment Banking Association (NIBA) conference. Thousands of investment professionals are involved with NIBA, representing more than 60 key industry services, along with 8,800+ registered representatives that have in excess of $78 billion in assets under management. To date, the association’s members have raised over $17 billion and are responsible for 90% of all Initial Public Offerings under $20 million.

Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers.

Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers that affect women. Recently, the battle against ovarian cancer has shifted strategy, and new optimism has come to the fore. Predictive models using artificial intelligence on large data sets of patient drug-treatment protocols and historical outcomes are now providing actionable intelligence for pharma to develop targeted therapeutics and for oncologists to prescribe the best course of treatment to improve individual patient outcomes. Predictive Oncology (NASDAQ: POAI) is laser focused on providing the molecular information critically needed to improve the lives of women stricken with ovarian cancer. The company has begun sequencing ovarian cancers as part of its CancerQuest2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. The rest of pharma is also racing to find solutions. Roche Holdings AG (OTCQX: RHHBY) acquired a molecular information company, is researching new ovarian specific drugs and is finding ways to identify the patients who will benefit most from detailed molecular information. GlaxoSmithKline PLC (NYSE: GSK) has developed a long-term approach to finding new cancer treatments by focusing attention in four key areas. AstraZeneca (NYSE: AZN) recently announced a new first-line maintenance treatment for advanced ovarian cancer. And Bristol-Myers Squibb (NYSE: BMY) has entered into clinical collaborations to evaluate drug combination therapeutic regimens for ovarian cancers.

As video streaming grows to dominate media consumption, companies are on the lookout for new ways to profit from the burgeoning trend.

Wonderfilm Media Corporation (TSXV: WNDR) (OTCQB: WDRFF) has developed a low-risk approach to content production by providing original works with top Hollywood talent. Apple Inc. (NASDAQ: AAPL) is launching its new TV+ service with a slew of big-name stars and big-budget productions. Netflix Inc. (NASDAQ: NFLX) continues to be a dominant player, with a strong mix of original and established content. The Walt Disney Company (NYSE: DIS) is using its range of high-profile entertainment brands to carve out its own place in the market. Lions Gate Entertainment Corporation (NYSE: LGF.A), which has produced content for other streamers, now has its own Latinx platform in the successful Pantaya.

The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving.

Predictive Oncology (NASDAQ: POAI) is in an enviable position in the precision-medicine industry due to its incredibly rich data set of more than 150,000 clinically validated cases on its molecular information platform, with 30,000-plus specific to ovarian cancer. The company is leveraging this unique database through Artificial Intelligence to provide the actionable insights needed to drive pharma R&D programs and improve patient outcomes. A data asset like this typically takes at least five years to fully validate and most competitors are only in the early stages of the process. Predictive Oncology already has it. The uniqueness of its data combined with its proprietary AI platform show true disruptive potential in the field of precision medicine. Leading pharma companies in the space such as Roche Holding AG (OTCQX: RHHBY), GlaxoSmithKline (NYSE: GSK), AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb (NYSE: BMY) have also shown keen interest in the promise of precision medicine and are making multibillion dollar investments in the space.

Advances in biotechnology look to deliver promising new treatment options against breast cancer.

Independent researchers have found that Genprex Inc.’s (NASDAQ: GNPX) (GNPX Profile) TUSC2 prevented tumor growth against triple-negative breast cancer. Eli Lilly and Company (NYSE: LLY) is focusing on those patients with the greatest need and, in the process, has developed a new breast-cancer treatment option. Roche Holding (OTCQX: RHHBY) is expanding the use of its biotech to both identify and treat patients with challenging breast cancers. AbbVie Inc. (NYSE: ABBV) has been rapidly increasing its research, targeting more than 15 different types of cancer. AstraZeneca (NYSE: AZN) has seen hopeful results against metastatic breast cancer as it works in collaboration with a Japanese firm.

Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer.

Genprex Inc. (NASDAQ: GNPX) is focused on using gene therapy to tackle lung cancer, developing new drugs that can be used alongside existing treatments. Pfizer Inc. (NYSE: PFE) has created a state-of-the-art research center focused on gene therapy treatments, which it uses for illnesses including cancer. Gilead Sciences Inc. (NASDAQ: GILD) is using biotechnology to tackle a range of challenging diseases, including HIV and hepatitis. Sarepta Therapeutics Inc. (NASDAQ: SRPT) is developing 20 different genetic treatments for a wide range of diseases. Merck & Company Inc. (NYSE: MRK) has treatments in development for both prostate and lung cancer, offering further hope for those battling potentially fatal diseases.

Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the drug-delivery technology used, and innovation in this space may have a huge impact on how successful a drug can be.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed one of the most innovative drug-delivery systems seen in years, a system that can be used to deliver a wide range of drugs in a more palatable and effective way. Seattle Genetics Inc. (NASDAQ: SGEN) is developing anti-cancer drugs whose delivery systems deliver killer treatments directly to harmful cells. Cancer-treatment company Exelixis Inc. (NASDAQ: EXEL) has recently entered into a partnership specifically to develop innovative new drugs. Axsome Therapeutics Inc. (NASDAQ: AXSM) uses a variety of delivery mechanisms to treat illnesses of the central nervous system, including narcolepsy, migraines and depression. Provention Bio Inc. (NASDAQ: PRVB) is focused on immune diseases and has recently seen significant progress in the development of lupus and diabetes drugs.

Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment.

Genprex Inc. (NASDAQ: GNPX) has completed key steps in its overall strategy to expand its clinical development programs and bring Oncoprex(TM) immunogene therapy, its lead drug candidate, to commercialization. Over the past five years, Amgen Inc. (NASDAQ: AMGN) has invested nearly $19 billion in R&D and, as a result, is now advancing a record number of clinical assets. Biogen Inc. (NASDAQ: BIIB) has added four new programs to its pipeline this quarter alone as the company continues to diversify and build depth within neuroscience and pursue therapeutic adjacencies. Celgene Corporation (NASDAQ: CELG) announced recently that its stockholders voted to approve the company’s proposed combination with Bristol-Myers Squibb Company (NYSE: BMY). This key milestone brings the two complementary biopharmaceutical companies one step closer to combining their efforts on a shared mission of discovering, developing and delivering innovative medicines for patients with serious diseases.

production and economic change in Indonesia.

Nickel is an essential component in batteries, including those for cars and phones.
Demand for metals is growing, most importantly in China, a major battery manufacturer.
Indonesia is the world’s largest nickel producer.
The country is working to expand its manufacturing sector, attracting investment from multinational industry and mining giants.

Pacific Rim Cobalt Corporation (OTCQB: PCRCF) (CSE: BOLT) is making the most of Indonesian nickel through an aggressive exploration and development program there. VALE S.A. (NYSE: VALE), the world’s leading nickel producer, is also invested in Indonesia. Lundin Mining Corporation (TSX: LUN) (OTC: LUNMF), another leading nickel producer, relies on sources in America and Europe. Cobalt 27 Capital Corporation (TSX.V: KBLT) (OTCQX: CBLLF) has recently acquired access to a significant Pacific nickel resource in Papua New Guinea. One of the major drivers behind this demand for batteries is car production by companies such as Honda Motor Company Ltd. (NYSE: HMC), which is moving more of its work to China.

Communication platforms are ubiquitous, yet first responders still have difficulty communicating in emergencies.

To meet the vital communication needs of first responders, Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) leveraged its strong commercial experience in mission-critical communications systems and launched its FirstNet Ready Uniden® UV350, the first-to-market, in-vehicle device of its kind. FirstNet is being built in a public-private partnership with AT&T Inc. (NYSE: T) and the First Responder Network Authority, an independent authority within the U.S. Department of Commerce. FirstNet is continuously expanding coverage, capacity and capability of the platform while first responders currently on the system receive fast, reliable broadband connectivity that consistently outperforms other networks. Motorola Solutions Inc. (NYSE: MSI) recently bought Kodiak Solutions, a Push-To-Talk software that is FirstNet enabled. Also in recent news, Sierra Wireless Inc. (NASDAQ: SWIR) introduced its AirLink MG90 High-Performance Multi-Network Vehicle Router now certified and approved for use on FirstNet, and in April Sonim Technologies Inc. (NASDAQ: SONM) released the Sonim XP3, a rugged handset on the FirstNet communications platform.

Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns.

Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) is leveraging its patented technology platform to deliver powerful tumor-suppressing genes directly into cancer cells. Calithera Biosciences Inc. (NASDAQ: CALA) is looking for cures for cancer and other life-threatening diseases by discovering, developing and commercializing novel, small-molecule drugs that target tumor and immune cell metabolism. Adaptimmune Therapeutics plc (NASDAQ: ADAP) is developing novel cancer immunotherapy products for cancer patients by engineering T-cells to target and destroy cancer. Agenus Inc. (NASDAQ: AGEN) is working on the discovery and development of therapies that engage the body’s immune system to fight cancer by pursuing combination approaches that leverage a broad range of antibody therapeutics, proprietary cancer vaccine platforms and adoptive cell therapies. G1 Therapeutics Inc. (NASDAQ: GTHX) is advancing three clinical-stage programs designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications.

Gene therapies are gaining growing attention within the medical sector.

• Gene therapies help restore or replace the body’s damaged or missing genes.
• Groundbreaking treatments can stop the spread of cancer cells, cause cancer cells to die.
• Gene therapies are also being developed for ailments such as migraines, skin conditions and hemophilia.

Genprex Inc. (NASDAQ: GNPX) is developing gene therapies for the treatment of cancer, including its initial drug candidate, Oncoprex(TM) immunogene therapy. Spark Therapeutics Inc. (NASDAQ: ONCE) is tackling hereditary diseases through treatments that augment, suppress or replace mutated genes. Dyadic International Inc. (OTCQX: DYAI) uses a fungus-based technology to deliver treatments, initially to humans, and now to animals. TrovaGene Inc. (NASDAQ: TROV) limits the growth of cancer through treatments that limit cell division. Novartis AG (NYSE: NVS) uses adeno-associated viruses as carriers for a range of treatments which are proving safe and effective in clinical trials.

Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable.

• Gene therapy is the next great leap forward in medicine, with several noteworthy programs underway looking to cure the incurable
• FDA expects 200 new gene and cell therapy INDs in next two years
• Genprex — and its initial product candidate Oncoprex — is pioneering a new approach to treating cancer.

Built on decades of scientific research and innovation, gene therapy is the next frontier of medicine, determined to provide remedies for previously untreatable diseases and unmet medical needs. At the forefront of this gene therapy revolution, Genprex Inc. (NASDAQ: GNPX) is pioneering a new paradigm in cancer therapeutics. The company’s first target is non-small cell lung cancer, and research indicates that Genprex’s novel technology might also deliver other cancer-fighting genes to combat a variety of different cancers. Sangamo Therapeutics Inc. (NASDAQ: SGMO) is conducting landmark studies to treat hemophilia, inherited metabolic disorders and other serious diseases at the genomic level. uniQure N.V. (NASDAQ: QURE) is leveraging its technology platform to advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases. bluebird bio Inc. (NASDAQ: BLUE) is developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. And Leap Therapeutics Inc. (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics.

Technology is transforming the automotive industry.

• Data is changing vehicle manufacturing and the way customers buy.
• Connectivity is transforming the relationships between customers and their vehicles.
• New technology such as blockchain provides alternative approaches to existing issues.
• The change affects the whole sector, from manufacturing and maintenance to sales.

Some of the innovation feeds off ideas from other industries, such as the vehicle repair app created by SinglePoint Inc. (OTCQB: SING). Some of it is focused on sales, as is the case for CDK Global Inc. (NASDAQ: CDK) and its dashboard to help with sales. There are innovations for specific market sectors, such as the truck data-gathering work headed by IHS Markit Ltd. (NASDAQ: INFO). Tesla Inc. (NASDAQ: TSLA) may be working on some of the highest profile changes, with its work on electric cars leading to record-breaking sales, but it’s the quieter work of companies such as AutoWeb Inc. (NASDAQ: AUTO) that is reaching into every corner of the market, as technology transforms the auto sales environment.